Dr. Rekdal is Co-founder of and served as CEO during the first 4 years of Lytix Biopharma’s formation.
After that he served as CSO and Head of R&D before he again was promoted to the position of CEO in 2019. Rekdal`s research background is within tumor immunology and his field of expertise is anticancer molecules derived from host defense peptides. Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996, and his postdoctoral work forms the basis of Lytix Biopharma’s technology peptide platform.
Dr. Rekdal has been instrumental in establishing collaboration with several distinguished researchers and institutions and is regularly invited to give plenary lectures at international oncology, industry and partnering conferences.
Gjest Breistein, MSc, CFO
Mr. Breistein has extensive experience as an auditor and consultant. Prior to joining Lytix in 2017, he worked at PwC advising public and private companies across multiple industry sectors in capital market transactions, financing and listing processes.
Mr. Breistein is a state authorized public accountant, and holds a Masters in Applied Economics and Finance from Copenhagen Business School, as well as a Masters in Professional Accountancy from BI Norwegian School of Management.
Baldur Sveinbjørnsson, PhD, CSO
Dr. Sveinbjørnsson achieved his doctorate at the Medical Faculty of the University of Tromsø in 1998, with a focus on mechanisms and mediators behind immunomodulation of experimental tumors. Since then, Dr. Sveinbjørnsson has gained a broad experience of preclinical oncology at the University of Tromsø and Karolinska Institutet Stockholm.
Dr. Sveinbjørnsson has been involved in the research activities of Lytix Biopharma since the beginning, and has most recently led the Company’s research activities as Chief Scientific Officer.
Gry Stensrud, PhD, CTO
Dr. Stensrud has more than 20 years of experience in research, development, clinical trials, commercial manufacturing and distribution of medicinal products and medical devices, as well as extensive leadership experience in developing biotech companies.
Dr. Stensrud has held different positions at GE Healthcare and prior to joining Lytix, Dr. Stensrud was Vice President Technical Development & Operations at Photocure. Dr. Stensrud holds a degree in Pharmacy and a PhD in Pharmaceutical Technology.
Marie-Louise Fjällskog, MD, PhD, Interim CMO
Dr. Fjällskog is a Senior Life Science Executive with more than 25 years of clinical experience as a medical oncologist within Clinical Research and Development, mainly Immuno-oncology. She is a Board Member of Biovica International AB, Sweden. Previously she has acted as Chief Medical Officer in Sensei Biotherapeutics and Faron Pharmaceuticals Ltd.
Dr. Fjällskog holds a PhD in Oncology and is an Associate Professor (docent) of Oncology affiliated to Uppsala University, Sweden.
Stephen T. Worsley, CBO
Mr. Worsley has more than 25 years experience with business development leadership in roles of increasing impact and in executing high-valuation strategic deals in the biopharmaceutical and drug discovery/development market. Most recently Mr. Worsley served as the Vice President Strategic Business Development at Redwood Biosciences/ Catalent Pharma Services. Mr. Worsley is a seasoned life sciences executive who also served roles as the CBO at Sutro Biopharma, Sr. Vice President Business Development at IndiMolecular and Vice President of Business Development at Peregrine Pharmaceutical (dba Avid Pharma Services) amongst other roles in his career.
As a business development executive, Mr. Worsley has led negotiations of transformative and award-winning technology and product partnerships for leading therapeutics companies.
Mr. Worsley holds an MBA from the University of Washington and a BS in Econ/International Finance from the University of Utah.